Cargando…
Immunotherapeutic treatment of inflammation in mice exposed to methamphetamine
INTRODUCTION: Currently, there are no FDA-approved medications to treat methamphetamine addiction, including the inflammatory, neurotoxic, and adverse neuropsychiatric effects. We have shown that partial (p)MHC class II constructs (i.e., Recombinant T-cell receptor Ligand – RTL1000), comprised of th...
Autores principales: | Loftis, Jennifer M., Ramani, Sankrith, Firsick, Evan J., Hudson, Rebekah, Le-Cook, Anh, Murnane, Kevin S., Vandenbark, Arthur, Shirley, Renee L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666795/ https://www.ncbi.nlm.nih.gov/pubmed/38025429 http://dx.doi.org/10.3389/fpsyt.2023.1259041 |
Ejemplares similares
-
Inflammatory and mental health sequelae of COVID-19
por: Loftis, Jennifer M., et al.
Publicado: (2023) -
Partial MHC/Neuroantigen Peptide Constructs: A Potential Neuroimmune-Based Treatment for Methamphetamine Addiction
por: Loftis, Jennifer M., et al.
Publicado: (2013) -
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
por: Brett, Jonathan, et al.
Publicado: (2023) -
Plasma Inflammatory Factors Are Associated with Anxiety, Depression, and Cognitive Problems in Adults with and without Methamphetamine Dependence: An Exploratory Protein Array Study
por: Huckans, Marilyn, et al.
Publicado: (2015) -
Associations of executive function and age of first use of methamphetamine with methamphetamine relapse
por: Mu, Lin-Lin, et al.
Publicado: (2022)